1. Ng, SC, Shi, HY, Hamidi, N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769–2778.
Google Scholar | Crossref | Medline2. Van Assche, G, Peyrin-Biroulet, L, Sturm, A, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – multicenter European cohort study. Dig Liver Dis 2016; 48: 592–600.
Google Scholar | Crossref | Medline3. Ungaro, R, Mehandru, S, Allen, PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756–1770.
Google Scholar | Crossref | Medline4. Ordás, I, Eckmann, L, Talamini, M, et al. Ulcerative colitis. Lancet 2012; 380: 1606–1619.
Google Scholar | Crossref | Medline | ISI5. GBD Inflammatory Bowel Disease Collaborators . The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5: 17–30.
Google Scholar | Crossref | Medline6. Solitano, V, D’Amico, F, Fiorino, G, et al. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. J Clin Med 2020; 9: 2905.
Google Scholar | Crossref7. Rubin, DT, Ananthakrishnan, AN, Siegel, CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114: 384–413.
Google Scholar | Crossref | Medline8. Borg-Bartolo, SP, Boyapati, RK, Satsangi, J, et al. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res 2020; 9: 54.
Google Scholar | Crossref9. Panés, J, Vermeire, S, Lindsay, JO, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in Phase 3 randomised controlled induction and maintenance studies. J Crohns Colitis 2018; 12: 145–156.
Google Scholar | Crossref | Medline10. Sandborn, WJ, Su, C, Sands, BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723–1736.
Google Scholar | Crossref | Medline11. Lewis, JD, Chuai, S, Nessel, L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660–1666.
Google Scholar | Crossref | Medline | ISI12. Lewis, JD, Lichtenstein, GR, Deren, JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008; 134: 688–695.
Google Scholar | Crossref | Medline13. Probert, CS, Sebastian, S, Gaya, DR, et al. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative colitis). BMJ Open Gastroenterol 2018; 5: e000212.
Google Scholar | Crossref | Medline14. Zezos, P, Kabakchiev, B, Weizman, AV, et al. Ulcerative colitis patients continue to improve over the first six months of vedolizumab treatment: 12-month clinical and mucosal healing effectiveness. J Can Assoc Gastroenterol 2020; 3: 74–82.
Google Scholar | Crossref | Medline15. Hanauer, S, Panaccione, R, Danese, S, et al. Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2019; 17: 139–147.
Google Scholar | Crossref | Medline16. Narula, N, Alshahrani, AA, Yuan, Y, et al. Patient-reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17: 411–418.e413.
Google Scholar | Crossref17. Agouridis, AP, Elisaf, M, Milionis, HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol 2011; 24: 181–187.
Google Scholar | Medline18. Semb, AG, Kvien, TK, Aastveit, AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) study. Ann Rheum Dis 2010; 69: 1996–2001.
Google Scholar | Crossref | Medline | ISI19. Sands, BE, Taub, PR, Armuzzi, A, et al. Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2020; 18: 123–132.e123.
Google Scholar | Crossref | Medline20. Charles-Schoeman, C, Fleischmann, R, Davignon, J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015; 67: 616–625.
Google Scholar | Crossref | Medline21. Smolen, JS, Genovese, MC, Takeuchi, T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019; 46: 7–18.
Google Scholar | Crossref | Medline22. Olivera, PA, Lasa, JS, Bonovas, S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2020; 158: 1554–1573.e1512.
Google Scholar | Crossref | Medline23. Kotyla, PJ, Islam, MA, Engelmann, M. Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci 2020; 21: 7390.
Google Scholar | Crossref24. Migita, K, Izumi, Y, Jiuchi, Y, et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis. Clin Exp Immunol 2014; 175: 208–214.
Google Scholar | Crossref | Medline25. Danese, S, Grisham, MB, Hodge, J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016; 310: G155–G162.
Google Scholar | Crossref | Medline26. Couronné, R, Probst, P, Boulesteix, AL. Random forest versus logistic regression: a large-scale benchmark experiment. BMC Bioinformatics 2018; 19: 270.
Google Scholar | Crossref | Medline27. Weber, C, Röschke, L, Modersohn, L, et al. Optimized identification of advanced chronic kidney disease and absence of kidney disease by combining different electronic health data resources and by applying machine learning strategies. J Clin Med 2020; 9: 2955.
Google Scholar | Crossref28. Sauthier, MS, Jouvet, PA, Newhams, MM, et al. Machine learning predicts prolonged acute hypoxemic respiratory failure in pediatric severe influenza. Crit Care Explor 2020; 2: e0175.
Google Scholar | Crossref | Medline